Press Release: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn., March 26, 2024 (GL

Dow JonesMar 26 08:01 ET

Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark

Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark

Dow JonesMar 21 10:16 ET

Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target

Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.

BenzingaMar 21 10:06 ET

Intensity Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma

BenzingaMar 21 10:03 ET

Express News | Intensity Therapeutics Shares Are Are Trading Higher After the Company Reported a Year-over-year Increase in FY24 EPS Results

Moomoo 24/7Mar 15 12:13 ET

Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY

Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril

BenzingaMar 14 16:29 ET